JSAM
CYTK icon

J. Safra Asset Management’s Cytokinetics CYTK Stock Holding History

J. Safra Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-309
Closed -$20.4K – 652
2026
Q1 		$20.4K Sell
309
-5,982
-95% -$380K ﹤0.01% 307
2025
Q4 		$400K Buy
6,291
+952
+18% +$59.2K 0.02% 175
2025
Q3 		$293K Buy
5,339
+1,652
+45% +$68.1K 0.02% 150
2025
Q2 		$122K Buy
3,687
+593
+19% +$20.6K 0.01% 177
2025
Q1 		$124K Buy
3,094
+1,343
+77% +$61.7K 0.01% 159
2024
Q4 		$82.6K Buy
1,751
+671
+62% +$34.8K 0.01% 170
2024
Q3 		$56.5K Buy
1,080
+553
+105% +$30.8K 0.01% 155
2024
Q2 		$28.6K Buy
527
+456
+642% +$27.5K ﹤0.01% 170
2024
Q1 		$4.98K Buy
+71
New +$5.49K ﹤0.01% 157

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

J. Safra Asset Management's CYTK Position: Q2 2026 in Review

J. Safra Asset Management sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 309 shares — an estimated $20.4K sold.

J. Safra Asset Management first reported a position in CYTK in Q1 2024 and held it in 9 quarters. The position peaked at $400K in Q4 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • J. Safra Asset Management reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
  • J. Safra Asset Management sold 309 Cytokinetics shares in Q2 2026, an estimated $20.4K.
  • J. Safra Asset Management first reported a position in Cytokinetics in Q1 2024 and held it in 9 quarters.
  • J. Safra Asset Management's Cytokinetics position peaked at $400K in Q4 2025.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on J. Safra Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.